marginally significantP = 0.055
VEGF-C was predictive for benefit from adjuvant treatment with paclitaxel (E-T-CMF arm) for OS (test for interaction, Wald's P = 0.038), and marginally significant for DFS (test for interaction, Wald's P = 0.055).
VEGF-C was predictive for benefit from adjuvant treatment with paclitaxel (E-T-CMF arm) for OS (test for interaction, Wald's P = 0.038), and marginally significant for DFS (test for interaction, Wald's P = 0.055).